

Article

##-Unsaturated N-Acylindoles: an Alternative Class of Michael Acceptors and Their Application in Asymmetric Borylation

Quanbin Jiang, Tenglong Guo, Runli Gao, Quannan Wang, Jiang Lou, and Zhengkun Yu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b00831 • Publication Date (Web): 25 May 2018

Downloaded from <http://pubs.acs.org> on May 26, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications

is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

α,β -Unsaturated *N*-Acylindoles: an Alternative Class of Michael Acceptors and Their Application in Asymmetric Borylation

Quanbin Jiang,^{†,‡} Tenglong Guo,^{†,‡} Runli Gao,^{‡,§} Quannan Wang,^{†,‡} Jiang Lou,^{†,‡} and Zhengkun Yu^{*,†,§}


[†] Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, People's Republic of China

^{*} State Key Laboratory of NBC Protection for Civilian, Yang Fang Town, Changping District, Beijing 102205, People's Republic of China

[‡] University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

[§] State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, People's Republic of China

RECEIVED DATE (will be automatically inserted after manuscript is accepted).



ABSTRACT: Copper(I)-catalyzed enantioselective borylation of α,β -unsaturated *N*-acylindoles as well as *N*-acylpyrroles was efficiently achieved by means of bis(pinacolato)diboron (B_2pin_2), affording the enantioenriched products in excellent yields with up to 99% ee. The present work provides an alternative class of Michael acceptors, that is, α,β -unsaturated *N*-acylindoles, for potential asymmetric transformations.

INTRODUCTION

Enantioselective conjugate additions of nucleophiles to α,β -unsaturated carbonyl compounds are among the most fundamental and important reactions in organic synthesis.¹ Numerous useful products bearing diverse functional groups can be obtained due to the broad scopes of the acceptors and donors. As compared to α,β -unsaturated ketones which have been widely used in asymmetric additions, the corresponding α,β -unsaturated esters and amides usually exhibit relatively low reactivities. Thus, a few functional groups have been brought in as ester and amide surrogates in order to improve their reactivities. In this regard, α,β -unsaturated oxazolidinones,² acyl imidazoles,³ acyl pyrrazoles,⁴ and acyl pyrroles⁵ have been reported as the surrogates of α,β -unsaturated esters and amides in asymmetric transformations. Among the above-mentioned compounds, α,β -unsaturated *N*-acylpyrroles are monodentate coordinative acceptors, others are bidentate coordinative ones. The former has the LUMO energy similar to that of α,β -unsaturated ketones due to the delocalization of the lone electron pair of the nitrogen atom into the pyrrolyl ring and the reduced donation to the carbonyl group.⁶ Therefore, α,β -unsaturated *N*-acylpyrroles can exhibit reactivity similar to that of α,β -unsaturated ketones, which is much higher than those of the corresponding esters and amides. Accordingly, α,β -unsaturated *N*-acylpyrroles have been widely investigated as the surrogates of α,β -unsaturated esters and amides in asymmetric synthesis.⁵ Indole motifs are more abundant than pyrrole functionalities in bioactive compounds and natural products, and indole derivatives have become more and more


attractive in the research areas of materials, agricultural chemicals, and pharmaceuticals.⁷ However, only one α,β -unsaturated *N*-acylindole, that is, *N*-cinnamoylindole, has been documented for asymmetric spirannulation to date, and such a *N*-acylindole substrate could not behave as an effective acceptor under the stated conditions.⁸

Chiral organoboron derivatives are versatile reagents in organic synthesis,⁹ and have been widely used as precursors for the construction of chiral C-O, C-N, and C-C bonds with the retention of enantiopurity.¹⁰ Enantioselective conjugate addition of diboron reagents to α,β -unsaturated carbonyls and related compounds has emerged as one of the most powerful tools for the preparation of chiral organoboron compounds due to the high reactivity and broad applicability of the substrates.^{9,11} In this area, copper catalysis¹² has been widely applied for asymmetric borylation although other transition-metal-catalyzed¹³ and organocatalytic¹⁴ methods have also been documented. Herein, We disclose copper-catalyzed enantioselective borylation of α,β -unsaturated *N*-acylindoles with bis(pinacolato)diboron (B_2pin_2), and α,β -unsaturated *N*-acylpyrroles were also explored for the same transformations.

RESULTS AND DISCUSSION

Initially, the Wittig^{5g} and Horner–Wadsworth–Emmons (HWE)^{5f} reactions were utilized to prepare α,β -unsaturated *N*-acylpyrroles by the literature methods. Unfortunately, these traditional methods usually suffer from obvious drawbacks such as use of air- and moisture-sensitive organolithium reagents, anaerobic manipulations,


time-consuming multistep procedures, and generation of stoichiometric wastes. In this communication, we used a phase transfer catalysis procedure¹⁵ for the synthesis of α,β -unsaturated *N*-acylpyrroles and *N*-acylindoles in the presence of *n*-Bu₄NHSO₄ catalyst and NaOH base (eq 1). This method features ready availability of the starting materials and easy manipulations as compared to the Wittig and HWE reactions.




Then, the reaction of (*E*)-1-(1*H*-indol-1-yl)-3-phenylprop-2-en-1-one (**1a**) with B₂pin₂ (**2**) in a 1.0:1.1 molar ratio was carried out to screen the reaction conditions (Table 1). In the presence of 5 mol % CuI as the catalyst, and 10 mol % K₃PO₄ as the base in *t*-AmOH at ambient temperature, a range of chiral ligands were tested for the asymmetric borylation of **1a**. In the case of using an axially chiral bisphosphine ligand such as (*R*)-BINAP (**L1**), the target product **3a** was obtained in a moderate yield (41%) with a very low enantioselectivity (Table 1, entry 1). Use of both (*S,S*)-Me-Duphos (**L2**) and (*S,S,R,R*)-Tangphos (**L3**) ligands led to **3a** in 95% yield, but the ee values were not satisfactory (Table 1, entries 2 and 3). To our delight, the chiral ligand with a ferrocenyl backbone, that is, (*R,S*)-Josiphos (**L4**), promoted the reaction to afford the target product in excellent yield (95%) with 95% ee (Table 1, entry 4). Either of (*R*)-(*S*)-NMe₂-PPh₂-Mandphos (**L5**) and (*R,R*)-Walphos (**L6**) ligands did not work well for the reaction (Table 1, entries 5 and 6). Although use of (*R,R*)-Taniaphos (**L7**) resulted in an excellent enantioselectivity (99% ee), the target product was only formed in 16% yield (Table 1, entry 7). CuI acted as the most

efficient catalyst as compared to CuCl and CuBr (Table 1, entries 8 and 9). Lowering the loading of CuI catalyst to 2.5 mol % and the amount of (*R,S*)-Josiphos to 3.75 mol % obviously deteriorated the reaction efficiency (Table 1, entry 10).

Table 1. Screening of Reaction Conditions^a



entry	[Cu] cat.	ligand	yield ^b (%)	ee ^c (%)
1	CuI	L1	41	-4
2	CuI	L2	95	-50
3	CuI	L3	95	-4
4	CuI	L4	99 (95) ^d	95
5	CuI	L5	22	-56
6	CuI	L6	25	-19
7	CuI	L7	16	99
8	CuCl	L4	0	
9	CuBr	L4	79	95
10 ^e	CuI	L4	83	93




















^a Conditions: **1a** (0.2 mmol), **2** (0.22 mmol), [Cu] (5 mol %), ligand (7.5 mol %), K₃PO₄ (10 mol %), *t*-AmOH (2 mL), 0.1 MPa N₂, 25 °C, 20 h. ^b ¹H NMR yield using CH₂Br₂ as the internal standard. ^c Determined by chiral HPLC analysis using an AD-H column. ^d Isolated yield given in parentheses. ^e CuI, 2.5 mol %; ligand, 3.75 mol %; K₃PO₄, 5 mol %.

Having established the optimized reaction conditions, we tested a variety of α,β -unsaturated *N*-acylindoles (**1**) to probe into the substrate diversity (Table 2). *N*-Acylindoles bearing a methyl group at 3- to 7-positions of the indole ring showed good reactivities to react with **2**, forming the target products **3c-3g** in excellent yields (94-96%) with 92-99% enantioselectivities. The steric hindrance from 2-methyl group on the indole ring slightly lessened the enantioselectivity, leading to **3b** in 96% yield with 88% ee. 5-Methoxy-substituted *N*-acylindole (**1h**) efficiently reacted with **2** to give **3h** (95% yield, 92% ee). 5-Halo-bearing *N*-acylindoles (halo = F, Cl, Br) reacted to produce **3i-3k** in 93-95% yields with 94-95% ee, demonstrating no substituent effect from the 5-substituent on the indole ring. Next, α,β -unsaturated *N*-acylindoles with various substituents at β -position were investigated. Variation of the methyl substituent at 4-, 3-, and 2-positions of the β -aryl functionality slightly lessened the enantioselectivities of products **3l-3n** from 93% to 90% ee with 94-96% yields.

4-OMe, 4-F, and 4-Cl on the β -aryl ring ensured 94-95% ee for products **3o-3q**. Sterically hindered β -(1-naphthyl)- α,β -unsaturated *N*-acylindole reacted with **2** less efficiently, affording **3r** in 88% yield and 87% ee. β -(2-Thienyl), methyl, ethyl, and propyl-functionalized substrates also reacted well with **2** to give **3s-3v** (80-95% yields, 90-96% ee).

Table 2. Enantioselective borylation of α,β -unsaturated *N*-acyl- indoles (1**) with **2**^{a,b,c}**














		
 (S)-3a , 94%, 95% ee	 (+)-3b , 96%, 88% ee	 (-)-3c , 94%, 92% ee ^e
 (-)-3d , 96%, 95% ee	 (+)-3e , 94%, 96% ee	 (-)-3f , 96%, 99% ee
 (+)-3g , 94%, 92% ee	 (-)-3h , 95%, 92% ee	 (-)-3i , 95%, 94% ee
 (-)-3j , 93%, 95% ee	 (-)-3k , 93%, 95% ee	 (-)-3l , 94%, 93% ee
 (-)-3m , 94%, 91% ee	 (-)-3n , 96%, 90% ee ^e	 (-)-3o , 95%, 94% ee



^a Conditions: **1** (0.2 mmol), **2** (0.22 mmol), *t*-AmOH (2 mL), 25 °C, 0.1 MPa N₂, 20 h. ^b Yield refers to the isolated products. ^c The ee values were determined by chiral HPLC analysis using an AD-H column. ^d 60 °C. ^e Determined by chiral HPLC analysis of the corresponding β-hydroxy compound by oxidation with sodium perborate.

In a similar manner, α,β-unsaturated *N*-acylpyrroles (**4**) were investigated in the asymmetric borylation with **2** (Table 3). β-Aryl-*N*-acylpyrroles could efficiently react with **2** under the standard conditions, giving the target products **5a-5c**, and **5e-5g** in 83-95% yields with excellent enantioselectivities (94-96% ee). Only in the case of using the substrate bearing a β-(2-methyl)phenyl moiety (**4d**), the reaction efficiency was slightly deteriorated to form **5d** (87%) with 90% ee. The lower enantioselectivities of **3b**, **3n**, **3r**, and **5d** may be due to the steric hindrance of substrates. A minor steric effect was also observed from β-(1-naphthyl) in product **5h**. The *N*-acylpyrroles containing a β-(2-thienyl) or β-methyl functionality efficiently underwent the reactions to form **5i** (92%, 96% ee) and **5j** (93%, 92% ee), respectively. However, β-ethyl and propyl obviously lessened the reaction efficiencies to afford **5k** (73%, 84% ee) and **5l** (77%, 90% ee).

Table 3. Enantioselective borylation of α,β-unsaturated *N*-acylpyrroles (**4**) with **2**^{a,b,c}


(S)-**5a**, 95%, 95% ee(+) - **5b**, 93%, 94% ee(+) - **5c**, 92%, 94% ee(+) - **5d**, 87%, 90% ee^e(+) - **5e**, 93%, 96% ee(+) - **5f**, 94%, 96% ee(+) - **5g**,^d 83%, 94% ee(+) - **5h**,^d 86%, 91% ee(−) - **5i**, 92%, 96% ee(−) - **5j**, 93%, 92% ee(−) - **5k**, 73%, 84% ee(−) - **5l**,^d 77%, 90% ee

^a Conditions: **4** (0.2 mmol), **2** (0.22 mmol), *t*-AmOH (2 mL), 25 °C, 0.1 MPa N₂, 20 h. ^b Yield refers to the isolated products. ^c The ee values were determined by chiral HPLC analysis using an AD-H column. ^d 60 °C. ^e Determined by chiral HPLC analysis of the corresponding β-hydroxy compound by oxidation with sodium perborate.


Because the enantiomers of products **3c**, **3n**, **3r**, and **5d** could not be separated on the chiral HPLC columns, they were converted to the corresponding β-hydroxy compounds through oxidation with sodium perborate in order to determine the ee values. Retention of the enantiopurity during this transformation was confirmed by oxidizing compounds **3a** to **6a**, and **5a** to **6e** (Table 4). Similar transformations were thus conducted for **3c**, **3n**, **3r**, and **5d**, affording the corresponding deborylated chiral products, that is, chiral β-hydroxy-amides **6b-6d** and **6f**, in good to excellent yields

(76-90%) with retention of enantiopurities (88-92%). Additional transformations were also conducted to demonstrate the utility of compounds **3** and **5** as ester and amide surrogates. However, treatment of **3a** or **5a** with NaOMe only led to trace amount of the target methyl esters through ^1H NMR analysis of the reaction mixtures, which is presumably attributed to the unstability of the borylated products under the strong basic conditions. To our delight, the reactions of **3a** and **5a** with pyrrolidine gave the corresponding amide **7** in good yields (71-80%) with retention of the enantioselectivities (eq 2). Compound **7** was assigned to be (*S*)-configuration by comparison of its optical rotation with the reported data.^{12j} Thus, chiral **3a** and **5a** were assigned to be (*S*)-configuration, and the configurations of other chiral products were assigned by analogy.


Table 4. Oxidative deborylation of compounds **3 and **5**^{a,b,c}**




^a Conditions: **3** or **5** (0.2 mmol), THF (1 mL), H_2O (1 mL), $25\text{ }^\circ\text{C}$, 2 h. ^b Yields refer to the isolated products. ^c The ee values were determined by chiral HPLC analysis using an AD-H column.




Control reactions were performed to determine the reactivity difference between α,β -unsaturated *N*-acylindoles and *N*-acetylpyrroles. An equimolar mixture of **1a** and **4a** was reacted with **2** under the standard conditions to give a mixture of **3a** (39%) and **5a** (42%) (eq 3), revealing that the α,β -unsaturated *N*-acylindole and *N*-acetylpyrrole have a similar reactivity in the asymmetric borylation reaction. Although **3a** reacted with pyrrolidine to afford **7** in a relative high yield (80% vs 71%) than the same reaction of **5a** did under the standard conditions (eq 2), the competition reactions of **3a** and **5a** with pyrrolidine suggested that compound **5a** reacted much faster than **3a** (eq 4). The asymmetric borylation reactions of α,β -unsaturated ketone **8** and ester **9** with **2** were also conducted under the standard conditions (eq 5), forming the target products **10** and **11** in 78-79% yields with 84-90% ee which are much lower than those from the reactions of the corresponding *N*-acylindoles and *N*-acetylpyrroles (Tables 3 and 4). These results have demonstrated the unique reactivity of *N*-acylindoles and *N*-acetylpyrroles as Michael acceptors.





A plausible mechanism is proposed in Scheme 1.¹⁶ The copper(I) salt initially reacts with B_2pin_2 (**2**) in the presence of a chiral phosphine ligand to generate Cu(I)-Bpin species **A**. Addition of **A** to α,β -unsaturated *N*-acylindole (**1**) or *N*-acypyrrole (**4**) leads to the organocopper(I) intermediate **B**. Subsequent protonation of **B** with the alcohol solvent *t*-AmOH affords the target product **3** or **5** with release of copper(I) alkoxide **C**. Interaction of species **C** with **2** regenerates the catalytically active species **A** to accomplish the catalytic cycle.

Scheme 1. Proposed mechanism



In conclusion, copper-catalyzed enantioselective borylation of α,β -unsaturated *N*-acylindoles and *N*-acylpyrroles with bis(pinacolato)diboron has been developed. Under the mild conditions, chiral organoboron compounds were obtained in high yields and enantioselectivities. This work provides an alternative class of Michael acceptors for conjugate additions.

EXPERIMENTAL SECTION

General Considerations. The solvents were dried and distilled prior to use by the literature methods. ^1H and ^{13}C spectra were recorded on a 400 MHz NMR spectrometer. In the ^{13}C NMR data, for many of the B-containing compounds, the signal to noise ratio was low for the carbon atom bound to Boron, which appear as broad signals likely due to quadrupolar relaxation.^{12j} As a result, we have not assigned a value for the chemical shift in the tabulated ^{13}C NMR data below. HRMS data was obtained by ESI on a Q-TOF mass spectrometer. Enantiomeric excess was determined by chiral HPLC analysis. Optical rotations were measured by an olarimeter. All the chemical reagents were purchased from commercial sources and used as received unless otherwise indicated. Compounds **1a**,¹⁷ **1c**,¹⁸ **1e**,¹⁷ **1h-1k**,¹⁷ **1o**,¹⁷ **1t**,¹⁹ **4a**,^{5g} **4b**,^{5g} **4c**,²⁰ **4d**,²⁰ **4e**,^{5g} **4f**,^{5e} **4g**,^{5g} **4h**,^{5g} **4i**,^{5g} **4j**,²¹ **4k**,²² **4l**,^{5f} **7**,^{12j} **10**,²³ **11**²⁴ were known and their spectroscopic features are in good agreement with those reported in the literatures.

General Procedure for the Synthesis of α,β -unsaturated *N*-acylindoles **1** and

pyrroles 4. Indole or pyrrole (2.0 mmol) and *n*-Bu₄NHSO₄ (340 mg, 1.0 mmol) were dissolved in CH₂Cl₂ (10 mL). Powdered NaOH (200 mg, 5.0 mmol) was added, and then α,β -unsaturated acyl chloride (3.0 mmol) in CH₂Cl₂ (5 mL) was introduced dropwise to the vigorously stirring solution. Stirring was continued at ambient temperature for 12 h. All the volatiles were evaporated under reduced pressure. The resulting residue was purification by silica gel column chromatography to afford the desired product **1** or **4**.

(E)-1-(2-Methyl-1H-indol-1-yl)-3-phenylprop-2-en-1-one (**1b**). 256 mg, 49% yield; yellow solid, mp 112-114 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 15.7 Hz, 1 H), 7.78-7.75 (m, 1 H), 7.65-7.63 (m, 2 H), 7.52-7.50 (m, 1 H), 7.47-7.45 (m, 3 H), 7.28-7.21 (m, 3 H), 6.42 (s, 1 H), 2.67 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 166.4, 145.7, 137.7, 136.2, 134.6, 130.9, 129.9, 129.2, 128.5, 123.1, 122.9, 121.4, 120.2, 114.4, 108.6, 16.3; HRMS (ESI) calcd for C₁₈H₁₆NO [M+H]⁺ 262.1226, found 262.1230.

(E)-1-(4-Methyl-1H-indol-1-yl)-3-phenylprop-2-en-1-one (**1d**). 256 mg, 49% yield; yellow solid, mp 98-100 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 8.3 Hz, 1 H), 7.99 (d, *J* = 15.4 Hz, 1 H), 7.62-7.60 (m, 3 H), 7.45-7.40 (m, 3 H), 7.37-7.33 (m, 1 H), 7.19 (d, *J* = 15.4 Hz, 1 H), 7.15 (d, *J* = 7.3 Hz, 1 H, aromatic CH), 6.71 (d, *J* = 3.5 Hz, 1 H), 2.57 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 164.0, 146.1, 135.5, 134.2, 130.5, 130.1, 128.8, 128.2, 124.9, 124.1, 124.0, 117.0, 114.3, 107.3, 18.4; HRMS (ESI) calcd for C₁₈H₁₆NO [M+H]⁺ 262.1226, found 262.1232.

(E)-1-(6-Methyl-1H-indol-1-yl)-3-phenylprop-2-en-1-one (**1f**). 219 mg, 42% yield;

yellow solid, mp 63-65 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.48 (s, 1 H), 8.00 (d, J = 15.4 Hz, 1 H), 7.64-7.62 (m, 2 H), 7.56 (d, J = 3.8 Hz, 1 H), 7.50 (d, J = 7.9 Hz, 1 H), 7.45-7.44 (m, 3 H), 7.22 (d, J = 15.4 Hz, 1 H), 7.17 (d, J = 7.9 Hz, 1 H), 6.66 (d, J = 3.7 Hz, 1 H), 2.55 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2, 146.3, 136.3, 135.1, 134.4, 130.7, 129.0, 128.4, 125.3, 124.0, 120.5, 117.3, 117.1, 109.1, 22.0; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 262.1226, found 262.1235.

(E)-1-(7-Methyl-1H-indol-1-yl)-3-phenylprop-2-en-1-one (**1g**). 282 mg, 54% yield; yellow solid, mp 105-107 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, J = 15.6 Hz, 1 H), 7.65 (s, 2 H), 7.55-7.47 (m, 5 H), 7.30-7.26 (m, 1 H), 7.23-7.16 (m, 2 H), 6.69 (s, 1 H), 2.62 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3, 146.6, 135.2, 134.3, 132.2, 130.9, 129.1, 126.2, 128.5, 127.8, 126.8, 124.0, 119.4, 118.8, 108.4, 22.1; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 262.1226, found 262.1233.

(E)-1-(1H-indol-1-yl)-3-(*p*-tolyl)prop-2-en-1-one (**1l**). 480 mg, 92% yield; yellow solid, mp 120-122 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.62 (d, J = 8.3 Hz, 1 H), 7.98 (d, J = 15.4 Hz, 1 H), 7.64-7.61 (m, 2 H), 7.52 (d, J = 8.0 Hz, 2 H), 7.41 (t, J = 7.4 Hz, 1 H), 7.33 (t, J = 7.4 Hz, 1 H), 7.23 (d, J = 7.9 Hz, 2 H), 7.18 (d, J = 15.4 Hz), 6.69 (d, J = 3.7 Hz), 2.40 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 146.5, 141.3, 136.0, 131.7, 130.6, 129.8, 128.4, 124.9, 124.7, 123.7, 120.9, 116.9, 116.1, 109.0, 21.5; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 262.1226, found 262.1228.

(E)-1-(1H-indol-1-yl)-3-(*m*-tolyl)prop-2-en-1-one (**1m**). 433 mg, 83% yield; pale yellow solid, mp 100-102 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.65 (d, J = 8.2 Hz, 1 H), 7.98 (d, J = 15.4 Hz, 1 H), 7.65-7.62 (m, 2 H), 7.43-7.41 (m, 3 H), 7.33 (td, J = 7.5,

2.6 Hz, 2 H), 7.26 (s, 1 H), 7.21 (d, $J = 15.4$ Hz, 1 H), 6.70 (d, $J = 3.5$ Hz, 1 H), 2.42 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2, 146.6, 138.6, 135.9, 134.3, 131.6, 130.6, 129.0, 128.9, 125.6, 124.9, 124.7, 123.7, 120.9, 116.89, 116.86, 109.0, 21.3; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 262.1226, found 262.1232.

(*E*)-1-(1*H*-indol-1-yl)-3-(*o*-tolyl)prop-2-en-1-one (**1n**). 277 mg, 53% yield; yellow solid, mp 58-59 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.58 (d, $J = 8.3$ Hz, 1 H), 8.31 (d, $J = 15.3$ Hz, 1 H), 7.69 (d, $J = 7.7$ Hz, 1 H), 7.66 (d, $J = 3.8$ Hz, 1 H), 7.62 (d, $J = 7.7$ Hz, 1 H), 7.41 (t, $J = 7.6$ Hz, 1 H), 7.35-7.30 (m, 2 H), 7.27 (d, $J = 7.2$ Hz, 2 H), 7.17 (d, $J = 15.3$ Hz, 1 H), 6.71 (d, $J = 3.7$ Hz, 1 H), 2.52 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 144.4, 138.3, 136.1, 133.6, 131.1, 130.7, 130.6, 126.5, 125.2, 124.7, 123.9, 121.0, 118.5, 116.9, 109.3, 20.0; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 262.1226, found 262.1234.

(*E*)-3-(4-Fluorophenyl)-1-(1*H*-indol-1-yl)prop-2-en-1-one (**1p**). 445 mg, 84% yield; white solid, mp 106-108 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.56 (d, $J = 8.1$ Hz, 1 H), 7.93 (d, $J = 15.4$ Hz, 1 H), 7.62-7.57 (m, 4 H), 7.41-7.37 (m, 1 H), 7.31 (td, $J = 7.6$, 1.0 Hz, 1 H), 7.15-7.07 (m, 3 H), 6.68 (d, $J = 3.6$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2 (d, $J = 250.6$ Hz), 164.1 (Cq, C=O), 145.2, 136.0, 130.73 (d, $J = 3.3$ Hz), 130.69, 130.4 (d, $J = 8.7$ Hz), 125.1, 124.6, 123.9, 121.0, 116.9, 116.2 (d, $J = 21.8$ Hz), 109.3, 117.0 (d, $J = 2.0$ Hz); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{13}\text{FNO}$ $[\text{M}+\text{H}]^+$: 266.0976, found 266.0985.

(*E*)-3-(4-Chlorophenyl)-1-(1*H*-indol-1-yl)prop-2-en-1-one (**1q**). 337 mg, 60% yield; white solid, mp 119-121 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 8.2$ Hz,

1 H), 7.87 (d, $J = 15.4$ Hz, 1 H), 7.57-7.54 (m, 2 H), 7.50 (d, $J = 8.4$ Hz, 2 H), 7.36-7.32 (m, 3 H), 7.28-7.21 (m, 1 H), 7.15 (d, $J = 15.4$ Hz, 1 H), 6.65 (d, $J = 3.8$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.0, 145.1, 136.8, 136.0, 133.0, 130.7, 129.6, 129.4, 125.2, 124.6, 124.0, 121.1, 117.9, 116.9, 109.4; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{13}\text{ClNO}$ $[\text{M}+\text{H}]^+$ 282.0680, found 282.0677.

(E)-1-(1*H*-indol-1-yl)-3-(naphthalen-1-yl)prop-2-en-1-one (**Ir**). 315 mg, 53% yield; yellow solid, mp 146-148 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.85 (d, $J = 15.2$ Hz, 1 H), 8.63 (d, $J = 8.2$ Hz, 1 H), 8.28 (d, $J = 8.3$ Hz, 1 H), 7.96-7.86 (m, 3 H), 7.68 (d, $J = 3.6$ Hz, 1 H), 7.64-7.52 (m, 4 H), 7.43 (t, $J = 7.7$ Hz, 1 H), 7.35-7.26 (m, 2 H), 6.72 (d, $J = 3.6$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.2, 143.7, 136.1, 133.8, 132.0, 131.7, 131.1, 130.8, 128.9, 127.2, 126.5, 125.5, 125.3, 125.2, 124.7, 124.0, 123.5, 121.1, 120.1, 117.0, 109.4; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 298.1226, found 298.1229.

(E)-1-(1*H*-indol-1-yl)-3-(thiophen-2-yl)prop-2-en-1-one (**Is**). 364 mg, 72% yield. pale yellow solid, mp 107-109 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, $J = 8.3$ Hz, 1 H), 8.11 (d, $J = 15.1$ Hz, 1 H), 7.63-7.59 (m, 2 H), 7.45 (d, $J = 5.0$ Hz), 7.40-7.37 (m, 2 H), 7.30 (t, $J = 7.4$ Hz), 7.11 (t, $J = 4.3$ Hz), 7.03 (d, $J = 15.1$ Hz), 6.70 (d, $J = 3.7$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.1, 139.8, 139.1, 136.0, 132.2, 130.8, 129.1, 128.5, 125.1, 124.7, 123.9, 121.0, 117.0, 115.9, 109.2; HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{12}\text{NOS}$ $[\text{M}+\text{H}]^+$ 254.0634, found 254.0637.

(E)-1-(1*H*-indol-1-yl)pent-2-en-1-one (**Iu**). 115 mg, 29% yield; yellow liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.39 (d, $J = 8.3$ Hz, 1 H), 7.45 (d, $J = 7.7$ Hz, 1 H), 7.41 (d,

$J = 3.7$ Hz, 1 H), 7.26-7.13 (m, 3 H), 6.53-6.49 (m, 2 H), 2.29-2.22 (m, 2 H), 1.05 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.5, 153.0, 136.0, 130.7, 125.0, 124.8, 123.8, 120.9, 120.0, 116.9, 109.0, 26.0, 12.4; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{14}\text{NO}$ $[\text{M}+\text{H}]^+$ 200.1070, found 200.1074.

(*E*)-1-(1*H*-indol-1-yl)hex-2-en-1-one (**1v**). 256 mg, 60% yield; colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, $J = 8.3$ Hz, 1 H), 7.60 (d, $J = 7.7$ Hz, 1 H), 7.57 (d, $J = 3.8$ Hz, 1 H), 7.41-7.37 (m, 1 H), 7.33-7.28 (m, 2 H), 6.70-6.66 (m, 2 H), 2.37 (qd, $J = 7.2, 1.5$ Hz, 2 H), 1.67-1.57 (m, 2H), 1.03 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 151.6, 136.0, 130.7, 125.0, 124.8, 123.8, 121.1, 120.9, 116.9, 109.0, 34.9, 21.6, 13.9; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$ 214.1226, found 214.1222.

A typical procedure for the enantioselective borylation of α,β -unsaturated *N*-acylindoles (1**) and *N*-acylpyrroles (**4**) with **B₂pin₂** (**2**) – Synthesis of (*S*)-**3a**.**

Under a nitrogen atmosphere, a mixture of CuI (1.9 mg, 0.01 mmol), (*R,S*)-JosiPhos (9.6 mg, 0.015 mmol), and K_3PO_4 (4.2 mg, 0.02 mmol) in *t*-AmOH (1 mL) was stirred at ambient temperature for 30 min, followed by the addition of **B₂pin₂** (**2**) (56 mg, 0.22 mmol) in *t*-AmOH (0.5 mL). After the mixture was stirred at ambient temperature for 10 min, (*E*)-1-(1*H*-indol-1-yl)-3-phenylprop-2-en-1-one (**1a**) (49 mg, 0.2 mmol) in *t*-AmOH (0.5 mL) was added. The resultant mixture was stirred at ambient temperature for 20 h, filtered through a short pad of celite, and rinsed with 20 mL EtOAc. All the volatiles were removed under reduced pressure, the resulting residue was purified by silica gel column chromatography (eluent: petroleum ether

(60-90 °C)/EtOAc = 50:1, v/v) to afford (*S*)-**3a** as a white solid (71 mg, 95%).

(*S*)-1-(1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**3a**). 71 mg, 95% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -23.4$ (c 1.0 CHCl₃); white solid, mp 90-92 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 8.2 Hz, 1 H), 7.59 (d, *J* = 7.7 Hz, 1 H), 7.46 (d, *J* = 3.5 Hz, 1 H), 7.40-7.25 (m, 7 H), 6.63 (d, *J* = 3.6 Hz, 1 H), 3.55 (dd, *J* = 17.2, 11.2 Hz, 1 H), 3.32 (dd, *J* = 17.2, 5.1 Hz, 1 H), 2.97 (dd, *J* = 11.1, 5.0 Hz, 1 H, CH), 1.32 and 1.24 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 141.2, 135.7, 130.4, 128.7, 128.5, 126.0, 125.0, 124.7, 123.6, 120.8, 116.6, 109.0, 83.7, 40.1, 24.7, 24.5; HRMS (ESI) calcd for C₂₃H₂₇BNO₃ [M+H]⁺ 376.2079, found 376.2084; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 220 nm, flow rate: 0.7 mL/min), *t*₁ = 7.3 min (maj.), *t*₂ = 8.0 min.

(+)-1-(2-Methyl-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**3b**). 75 mg, 96% yield; 88% ee, $[\alpha]_{\text{D}}^{20} = +5.0$ (c 1.0 CHCl₃); white solid, mp 100-102 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.02-8.00 (m, 1 H), 7.47-7.45 (m, 1 H), 7.36-7.31 (m, 4 H), 7.24-7.21 (m, 3 H), 6.37 (s, 1 H), 3.59 (dd, *J* = 17.0, 11.4 Hz, 1 H), 3.38 (dd, *J* = 17.0, 4.9 Hz, 1 H), 2.93 (dd, *J* = 11.3, 4.8 Hz, 1 H), 2.65 (s, 3 H), 1.27 and 1.20 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 141.3, 137.7, 136.4, 129.9, 128.7, 128.5, 125.9, 123.5, 123.0, 119.8, 115.6, 109.6, 83.5, 43.4, 24.6, 24.5, 17.9; HRMS (ESI) calcd for C₂₄H₂₉BNO₃ [M+H]⁺ 390.2235, found 390.2243; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.5 mL/min), *t*₁ = 13.2 min (maj.), *t*₂ = 14.6 min.

(-)-1-(3-Methyl-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-

n-2-yl)propan-1-one (**3c**). 73 mg, 94% yield; 92% ee, $[\alpha]_{\text{D}}^{20} = -20.2$ (c 1.0 CHCl₃); white solid, mp 137-139 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, *J* = 7.5 Hz, 1 H), 7.51 (d, *J* = 7.5 Hz, 1 H), 7.38-7.28 (m, 6 H), 7.25-7.20 (m, 2 H), 3.50 (dd, *J* = 17.1, 11.2 Hz, 1 H), 3.28 (dd, *J* = 17.2, 5.2 Hz, 1 H), 2.94 (dd, *J* = 11.1, 5.1 Hz, 1 H), 2.28 (s, 3 H), 1.29 and 1.21 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 141.4, 136.0, 131.4, 128.7, 128.5, 125.9, 125.1, 123.3, 121.7, 118.8, 118.2, 116.7, 83.7, 40.2, 24.7, 24.6, 9.8; HRMS (ESI) calcd for C₂₄H₂₉BNO₃ [M+H]⁺ 390.2235, found: 390.2238; enantioselectivity was determined by chiral HPLC analysis of the corresponding β-hydroxy compound (-)-**6a** by oxidation of (-)-**3c** with sodium perborate.

(-)-1-(4-Methyl-1H-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3d**). 75 mg, 96% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -7.2$ (c 1.0 CHCl₃); white solid, mp 103-105 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.32 (d, *J* = 8.3 Hz, 1 H), 7.47 (d, *J* = 3.8 Hz, 1 H), 7.37-7.19 (m, 6 H), 7.09 (d, *J* = 7.3 Hz, 1 H), 6.67 (d, *J* = 3.8 Hz, 1 H), 3.53 (dd, *J* = 17.2, 11.2 Hz, 1 H), 3.31 (dd, *J* = 17.2, 5.1 Hz, 1 H), 2.94 (dd, *J* = 11.2, 5.1 Hz, 1 H), 2.54 (s, 3 H), 1.28 and 1.20 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.4, 141.3, 135.5, 130.3, 130.0, 128.8, 128.5, 126.0, 125.2, 124.2, 124.0, 114.2, 107.4, 83.7, 40.2, 24.7, 24.6, 18.6; HRMS (ESI) calcd for C₂₄H₂₉BNO₃ [M+H]⁺ 390.2235, found 390.2239; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99.2/0.8, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 13.1 min, *t*₂ = 14.3 min (maj.).

(+)-1-(5-Methyl-1H-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3e**). 73 mg, 94% yield; 96% ee, $[\alpha]_{\text{D}}^{20} = +33.9$ (c 1.0 CHCl₃);

white solid, mp 142-144 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, J = 8.2 Hz, 1 H), 7.43 (d, J = 3.2 Hz, 1 H), 7.36-7.32 (m, 5 H), 7.24-7.17 (m, 2 H), 6.55 (d, J = 3.6 Hz, 1 H), 3.52 (dd, J = 17.1, 11.2 Hz, 1 H), 3.30 (dd, J = 17.2, 5.1 Hz, 1 H), 2.95 (dd, J = 11.1, 5.0 Hz, 1 H), 2.47 (s, 3 H), 1.29 and 1.21 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 141.3, 133.9, 133.1, 130.6, 128.8, 128.6, 126.4, 126.0, 124.8, 120.8, 116.3, 108.8, 83.7, 40.0, 24.7, 24.6, 21.5; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2243; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 9.3 min (maj.), t_2 = 11.0 min.

(-)-1-(6-Methyl-1H-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3f**). 75 mg, 96% yield; 99% ee, $[\alpha]_{\text{D}}^{20}$ = -3.0 (c 1.0 CHCl_3); white solid, mp 117-119 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1 H), 7.43 (d, J = 7.9 Hz, 1 H), 7.39 (d, J = 3.6 Hz, 1 H), 7.35-7.29 (m, 4 H), 7.22-7.18 (m, 1 H), 7.10 (d, J = 7.9 Hz, 1 H), 6.56 (d, J = 3.6 Hz, 1 H), 3.50 (dd, J = 17.1, 11.0 Hz, 1 H), 3.29 (dd, J = 17.2, 5.2 Hz, 1 H), 2.93 (dd, J = 10.9, 5.1 Hz, 1 H), 2.49 (s, 3 H), 1.27 and 1.19 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 141.3, 136.1, 135.1, 128.7, 128.5, 128.1, 126.0, 125.0, 124.1, 120.4, 116.9, 108.9, 83.7, 40.0, 24.7, 24.6, 22.0; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2242; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 10.0 min, t_2 = 12.6 min (maj.).

(+)-1-(7-Methyl-1H-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3g**). 73 mg, 94% yield; 92% ee, $[\alpha]_{\text{D}}^{20}$ = +7.8 (c 1.0 CHCl_3); white solid, mp 113-115 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.44 (d, J = 3.7 Hz, 1 H),

7.41 (d, $J = 7.5$ Hz, 1 H), 7.36-7.31 (m, 4 H), 7.24-7.14 (m, 3 H), 6.60 (d, $J = 3.6$ Hz, 1 H), 3.54 (dd, $J = 16.8, 10.6$ Hz, 1 H), 3.35 (dd, $J = 16.8, 5.5$ Hz, 1 H), 2.97 (dd, $J = 10.5, 5.5$ Hz, 1 H), 2.57 (s, 3 H), 1.28 and 1.23 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.6, 141.3, 135.3, 132.0, 128.8, 128.6, 128.1, 126.8, 126.2, 126.0, 124.0, 118.5, 108.9, 83.8, 40.6, 24.8, 24.5, 23.0; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2243; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 220 nm, flow rate: 0.7 mL/min), $t_1 = 14.4$ min, $t_2 = 16.6$ min (maj.).

(-)-1-(5-Methoxy-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**3h**). 77 mg, 95% yield; 92% ee, $[\alpha]_{\text{D}}^{20} = -35.2$ (c 1.0 CHCl_3); white solid, mp 156-158 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, $J = 8.8$ Hz, 1 H), 7.43 (d, $J = 3.3$ Hz, 1 H), 7.35-7.29 (m, 4 H), 7.22-7.19 (m, 1 H), 7.03 (d, $J = 2.1$ Hz, 1 H), 6.96 (dd, $J = 9.0, 2.2$ Hz, 1 H), 6.54 (d, $J = 3.6$ Hz, 1 H), 3.86 (s, 3 H), 3.49 (dd, $J = 17.1, 11.2$ Hz, 1 H), 3.28 (dd, $J = 17.1, 5.1$ Hz, 1 H), 2.92 (dd, $J = 11.1, 5.1$ Hz, 1 H), 1.27 and 1.19 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 156.5, 141.3, 131.4, 130.5, 128.8, 128.5, 126.0, 125.4, 117.4, 113.5, 108.9, 103.6, 83.7, 55.8, 39.9, 24.7, 24.6; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_4$ $[\text{M}+\text{H}]^+$ 406.2184, found 406.2187; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 10.4$ min (maj.), $t_2 = 12.2$ min.

(-)-1-(5-Fluoro-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**3i**). 75 mg, 95% yield; 94% ee, $[\alpha]_{\text{D}}^{20} = -12.8$ (c 0.5 CHCl_3); white solid, mp 128-130 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.43 (dd, $J = 8.9, 4.7$ Hz, 1 H), 7.50 (d, $J = 3.7$ Hz, 1 H), 7.34-7.29 (m, 4 H), 7.22-7.20 (m, 2 H), 7.08-7.03 (m,

1 H), 6.57 (d, $J = 3.7$ Hz, 1 H), 3.50 (dd, $J = 17.2, 11.1$ Hz, 1 H), 3.29 (dd, $J = 17.2, 5.2$ Hz, 1 H), 2.91 (dd, $J = 11.0, 5.1$ Hz, 1 H), 1.26 and 1.18 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 159.6 (d, $J = 238.4$ Hz), 141.1, 132.1, 131.3 (d, $J = 10.0$ Hz), 128.8, 128.5, 126.2, 126.0, 117.6 (d, $J = 9.0$ Hz), 112.7 (d, $J = 24.6$ Hz), 108.6 (d, $J = 3.9$ Hz), 106.3 (d, $J = 23.7$ Hz), 83.7, 39.8, 24.6, 24.5; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{26}\text{BFNO}_3$ $[\text{M}+\text{H}]^+$ 394.1984, found: 394.1989; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 220 nm, flow rate: 0.7 mL/min), $t_1 = 6.6$ min (maj.), $t_2 = 7.2$ min.

(-)-1-(5-Chloro-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3j**). 76 mg, 93% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -14.7$ (c 1.0 CHCl_3); white solid, mp 121-123 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.41 (d, $J = 8.8$ Hz, 1 H), 7.52 (d, $J = 2.0$ Hz, 1 H), 7.47 (d, $J = 3.7$ Hz, 1 H), 7.33-7.28 (m, 5 H), 7.23-7.19 (m, 1 H), 6.55 (d, $J = 3.7$ Hz, 1 H), 3.50 (dd, $J = 17.2, 11.1$ Hz, 1 H), 3.28 (dd, $J = 17.3, 5.2$ Hz, 1 H), 2.92 (dd, $J = 11.0, 5.2$ Hz, 1 H, CH), 1.27 and 1.19 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 141.1, 134.1, 131.6, 129.2, 128.8, 128.5, 126.1, 126.0, 125.2, 120.5, 117.7, 108.3, 83.8, 40.0, 24.7, 24.6; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{26}\text{BClNO}_3$ $[\text{M}+\text{H}]^+$ 410.1689, found 410.1698; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 14.8$ min (maj.), $t_2 = 21.0$ min.

(-)-1-(5-Bromo-1*H*-indol-1-yl)-3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (**3k**). 84 mg, 93% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -15.9$ (c 1.0 CHCl_3); white solid, mp 132-133 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.35 (d, $J = 8.8$ Hz, 1 H),

7.69 (d, $J = 1.9$ Hz, 1 H), 7.46 (d, $J = 3.8$ Hz, 1 H), 7.43 (dd, $J = 8.8, 1.9$ Hz, 1 H), 7.33-7.29 (m, 4 H), 7.20 (ddd, $J = 8.5, 5.9, 2.9$ Hz, 1 H), 6.55 (d, $J = 3.7$ Hz, 1 H), 3.49 (dd, $J = 17.2, 11.0$ Hz, 1 H), 3.28 (dd, $J = 17.3, 5.2$ Hz, 1 H), 2.91 (dd, $J = 11.0, 5.2$ Hz, 1 H), 1.26 and 1.18 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 141.1, 134.5, 132.1, 128.8, 128.5, 127.9, 126.1, 125.9, 123.6, 118.1, 116.9, 108.2, 83.8, 40.0, 24.7, 24.6; HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{26}\text{BBrNO}_3$ $[\text{M}+\text{H}]^+$ 454.1184, found 454.1187; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 9.0$ min (maj.), $t_2 = 10.6$ min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*p*-tolyl)prop-1-one (**3l**). 73 mg, 94% yield; 93% ee, $[\alpha]_{\text{D}}^{20} = -8.3$ (c 1.0 CHCl_3); white solid, mp 132-134 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.52 (d, $J = 8.2$ Hz, 1 H), 7.59 (d, $J = 7.6$ Hz, 1 H), 7.47 (d, $J = 3.8$ Hz, 1 H), 7.39-7.35 (m, 1 H), 7.29-7.26 (m, 3 H), 7.16 (d, $J = 7.8$ Hz, 2 H), 6.63 (d, $J = 3.6$ Hz, 1 H), 3.52 (dd, $J = 17.2, 11.1$ Hz, 1 H), 3.30 (dd, $J = 17.2, 5.2$ Hz, 1 H), 2.93 (dd, $J = 11.1, 5.1$ Hz, 1 H), 2.36 (s, 3 H), 1.31 and 1.23 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.4, 138.1, 135.8, 135.4, 130.4, 129.5, 128.4, 125.0, 124.7, 123.6, 120.9, 116.7, 109.0, 83.7, 40.3, 24.7, 24.6, 21.1; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2237; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.5 mL/min), $t_1 = 11.5$ min (maj.), $t_2 = 12.9$ min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*m*-tolyl)prop-1-one (**3m**). 73 mg, 94% yield; 91% ee, $[\alpha]_{\text{D}}^{20} = -2.7$ (c 1.0 CHCl_3); white solid, mp 104-105 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, $J = 8.2$ Hz, 1 H), 7.58 (d, $J =$

7.6 Hz, 1 H), 7.48 (d, $J = 3.8$ Hz, 1 H), 7.38-7.34 (m, 1 H), 7.30-7.26 (m, 1 H), 7.25-7.21 (m, 1 H), 7.17-7.15 (m, 2 H), 7.04 (d, $J = 7.4$ Hz, 1 H), 6.63 (d, $J = 3.8$ Hz, 1 H), 3.52 (dd, $J = 17.2, 11.3$ Hz, 1 H), 3.30 (dd, $J = 17.2, 5.1$ Hz, 1 H), 2.91 (dd, $J = 11.3, 5.1$ Hz, 1 H), 2.37 (s, 3 H), 1.29 and 1.21 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.4, 141.1, 138.3, 135.8, 130.4, 129.4, 128.7, 126.8, 125.5, 125.1, 124.8, 123.6, 120.9, 116.7, 109.0, 83.7, 40.2, 24.7, 24.6, 21.6; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2228; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 8.1$ min (maj.), $t_2 = 8.9$ min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*o*-tolyl)propan-1-one (**3n**). 75 mg, 94% yield; 90% ee, $[\alpha]_{\text{D}}^{20} = -8.8$ (c 1.0 CHCl_3); white solid, mp 84-86 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.51 (d, $J = 8.2$ Hz, 1 H), 7.58 (d, $J = 7.7$ Hz, 1 H), 7.47 (d, $J = 3.7$ Hz, 1 H), 7.38-7.34 (m, 2 H), 7.30-7.27 (t, $J = 7.5$ Hz, 1 H), 7.21-7.17 (t, $J = 7.7$ Hz, 2 H), 7.14-7.11 (t, $J = 7.1$ Hz, 1 H), 6.63 (d, $J = 3.7$ Hz, 1 H), 3.51 (dd, $J = 17.0, 10.9$ Hz, 1 H), 3.24 (dd, $J = 17.0, 4.8$ Hz, 1 H), 3.18 (dd, $J = 10.9, 4.8$ Hz, 1 H), 2.44 (s, 3 H), 1.29 and 1.21 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.5, 139.6, 136.6, 135.8, 130.8, 130.4, 127.9, 126.3, 125.9, 125.1, 124.8, 123.6, 120.9, 116.7, 109.0, 83.7, 39.5, 24.8, 24.6, 20.2. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{29}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 390.2235, found 390.2238; enantioselectivity was determined by chiral HPLC analysis of the corresponding β -hydroxy compound (-)-**6b** by oxidation of (-)-**3n** with sodium perborate.

(-)-1-(1*H*-indol-1-yl)-3-(4-methoxyphenyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboro

lan-2-yl)propan-1-one (3o). 77 mg, 95% yield; 94% ee, $[\alpha]_{\text{D}}^{20} = -12.5$ (c 1.0 CHCl₃); White solid, mp 147-148 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 8.2 Hz, 1 H), 7.57 (d, *J* = 7.7 Hz, 1 H), 7.46 (d, *J* = 3.7 Hz, 1 H), 7.37-7.33 (m, 1 H), 7.29-7.26 (m, 3 H), 6.88 (d, *J* = 8.6 Hz, 2 H), 6.61 (d, *J* = 3.7 Hz, 1 H), 3.80 (s, 3 H), 3.48 (dd, *J* = 17.2, 11.0 Hz, 1 H), 3.28 (dd, *J* = 17.2, 5.3 Hz, 1 H), 2.89 (dd, *J* = 10.9, 5.2 Hz, 1 H), 1.29 and 1.21 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.4, 158.0, 135.7, 133.1, 130.4, 129.4, 125.0, 124.7, 123.5, 120.8, 116.7, 114.2, 108.9, 83.7, 55.3, 40.4, 24.7, 24.6; HRMS (ESI) calcd for C₂₄H₂₉BNO₄ [M+H]⁺ 406.2184, found 406.2183; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.5 mL/min), *t*₁ = 13.8 min (maj.), *t*₂ = 14.9 min.

(-)-3-(4-Fluorophenyl)-1-(1H-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (3p). 71 mg, 90% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -13.5$ (c 0.2 CHCl₃); white solid, mp 130-132 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 8.2 Hz, 1 H), 7.57 (d, *J* = 7.7 Hz, 1 H), 7.45 (d, *J* = 3.7 Hz, 1 H), 7.38-7.25 (m, 4 H), 7.04-6.99 (m, 4 H), 6.62 (d, *J* = 3.8 Hz, 1 H), 3.47 (dd, *J* = 17.2, 10.8 Hz, 1 H), 3.28 (dd, *J* = 17.2, 5.4 Hz, 1 H), 2.92 (dd, *J* = 10.7, 5.3 Hz, 1 H), 1.29 and 1.21 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 161.4 (d, *J* = 242.3 Hz), 136.9 (d, *J* = 3.2 Hz), 135.7, 130.4, 129.9 (d, *J* = 7.7 Hz), 125.1, 124.7, 123.6, 120.9, 116.7, 115.5 (d, *J* = 21.0 Hz), 109.1, 83.8, 40.1, 24.7, 24.6; HRMS (ESI) calcd for C₂₃H₂₆BFNO₃ [M+H]⁺ 394.1984, found 394.1990; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 8.7 min (maj.), *t*₂ = 9.7 min.

(-)-3-(4-Chlorophenyl)-1-(1H-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)propan-1-one (3q). 71 mg, 90% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = -13.5$ (c 0.2 CHCl₃); white solid, mp 130-132 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 8.2 Hz, 1 H), 7.57 (d, *J* = 7.7 Hz, 1 H), 7.45 (d, *J* = 3.7 Hz, 1 H), 7.38-7.25 (m, 4 H), 7.04-6.99 (m, 4 H), 6.62 (d, *J* = 3.8 Hz, 1 H), 3.47 (dd, *J* = 17.2, 10.8 Hz, 1 H), 3.28 (dd, *J* = 17.2, 5.4 Hz, 1 H), 2.92 (dd, *J* = 10.7, 5.3 Hz, 1 H), 1.29 and 1.21 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 161.4 (d, *J* = 242.3 Hz), 136.9 (d, *J* = 3.2 Hz), 135.7, 130.4, 129.9 (d, *J* = 7.7 Hz), 125.1, 124.7, 123.6, 120.9, 116.7, 115.5 (d, *J* = 21.0 Hz), 109.1, 83.8, 40.1, 24.7, 24.6; HRMS (ESI) calcd for C₂₃H₂₆ClBFO₃ [M+H]⁺ 394.1984, found 394.1990; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 8.7 min (maj.), *t*₂ = 9.7 min.

n-2-yl)propan-1-one (**3q**). 75 mg, 92% yield; 94% ee, $[\alpha]_D^{20} = -6.4$ (c 0.5 CHCl₃); white solid, mp 135-137 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, *J* = 8.2 Hz, 1 H), 7.57 (d, *J* = 7.6 Hz, 1 H), 7.46 (d, *J* = 3.8 Hz, 1 H), 7.37-7.33 (m, 1 H), 7.30-7.26 (m, 5 H), 6.63 (d, *J* = 3.7 Hz, 1 H), 3.48 (dd, *J* = 17.2, 10.7 Hz, 1 H), 3.29 (dd, *J* = 17.2, 5.4 Hz, 1 H), 2.90 (dd, *J* = 10.7, 5.4 Hz, 1 H), 1.27 and 1.20 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 139.8, 135.8, 131.8, 130.4, 129.9, 128.9, 125.2, 124.6, 123.7, 121.0, 116.7, 109.2, 83.9, 39.9, 24.7, 24.6; HRMS (ESI) calcd for C₂₃H₂₆BClNO₃ [M+H]⁺ 410.1689, found 410.1700; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 16.0 min (maj.), *t*₂ = 18.0 min.

(+)-1-(1*H*-indol-1-yl)-3-(naphthalen-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-*an*-2-yl)propan-1-one (**3r**). 75 mg, 88% yield; 87% ee, $[\alpha]_D^{20} = +18.9$ (c 1.0 CHCl₃); white solid, mp 124-126 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 8.2 Hz, 1 H), 8.30 (d, *J* = 8.3 Hz, 1 H), 7.90 (d, *J* = 7.8 Hz, 1 H), 7.77 (d, *J* = 8.1 Hz, 1 H), 7.60-7.46 (m, 5 H), 7.41-7.38 (m, 2 H), 7.32-7.28 (m, 1 H), 6.59 (d, *J* = 3.7 Hz, 1 H), 3.79 (dd, *J* = 10.9, 4.5 Hz, 1 H), 3.67 (dd, *J* = 17.0, 10.9 Hz, 1 H), 3.40 (dd, *J* = 17.0, 4.5 Hz, 1 H), 1.35 and 1.24 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.4, 137.9, 135.8, 134.3, 132.1, 130.4, 129.0, 126.9, 126.1, 125.9, 125.74, 125.68, 125.1, 124.7, 124.0, 123.6, 120.9, 116.7, 109.0, 83.9, 39.8, 24.8, 24.6; HRMS (ESI) calcd for C₂₇H₂₉BNO₃ [M+H]⁺ 426.2235, found 426.2238; enantioselectivity was determined by chiral HPLC analysis of the corresponding β-hydroxy compound (-)-**6c** by oxidation of (+)-**3r** with sodium perborate.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(thiophen-2-yl)propan-1-one (**3s**). 69 mg, 91% yield; 96% ee, $[\alpha]_{\text{D}}^{20} = -56.0$ (c 0.1 CHCl₃); white solid, mp 99-101 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, *J* = 8.1 Hz, 1 H), 7.57 (d, *J* = 7.6 Hz, 1 H), 7.47 (d, *J* = 3.4 Hz, 1 H), 7.37-7.34 (m, 1 H), 7.29-7.26 (m, 1 H), 7.14 (d, *J* = 4.7 Hz, 1 H), 6.97-6.95 (m, 2 H), 6.63 (d, *J* = 3.6 Hz, 1 H), 3.51 (dd, *J* = 17.1, 10.6 Hz, 1 H), 3.41 (dd, *J* = 17.2, 5.1 Hz, 1 H), 3.22 (dd, *J* = 10.4, 5.1 Hz, 1 H), 1.31 and 1.25 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 143.9, 135.8, 130.4, 127.1, 125.2, 124.7, 123.7, 123.4, 120.9, 116.7, 109.2, 84.1, 40.9, 24.8, 24.6; HRMS (ESI) calcd for C₂₁H₂₅BNO₃S [M+H]⁺ 382.1643, found 382.1646; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 9.5 min (maj.), *t*₂ = 10.6 min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-1-one (**3t**). 59 mg, 95% yield; 92% ee, $[\alpha]_{\text{D}}^{20} = -27.5$ (c 0.1 CHCl₃); white solid, mp 96-97 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 8.2 Hz, 1 H), 7.56 (d, *J* = 7.7 Hz, 1 H), 7.48 (d, *J* = 3.8 Hz, 1 H), 7.37-7.32 (m, 1 H), 7.28-7.24 (m, 1 H), 6.61 (d, *J* = 3.7 Hz, 1 H), 3.09-2.98 (m, 2 H), 1.63-1.53 (m, 1 H), 1.29 and 1.27 (s each, 6:6 H), 1.15 (d, *J* = 7.5 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.7, 135.7, 130.4, 125.0, 124.8, 123.5, 120.8, 116.7, 108.7, 83.3, 39.8, 24.8, 24.7, 15.2. HRMS (ESI) calcd for C₁₈H₂₅BNO₃ [M+H]⁺ 314.1922, found 314.1926; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 6.8 min (maj.), *t*₂ = 7.6 min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentan-1-one

(**3u**). 52 mg, 80% yield; 92% ee, $[\alpha]_{\text{D}}^{20} = -37.3$ (c 1.0 CHCl₃); white solid, mp 75-77 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (d, *J* = 8.2 Hz, 1 H), 7.56 (d, *J* = 7.7 Hz, 1 H), 7.51 (d, *J* = 3.7 Hz, 1 H), 7.36-7.32 (m, 1 H), 7.28-7.24 (m, 1 H), 6.62 (d, *J* = 3.8 Hz, 1 H), 3.11-3.00 (m, 2 H), 1.69-1.58 (m, 1 H), 1.56-1.46 (m, 2 H), 1.28 and 1.26 (s each, 6:6 H), 1.02 (t, *J* = 7.3 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 135.8, 130.4, 125.0, 124.9, 123.5, 120.8, 116.7, 108.8, 83.3, 37.7, 24.9, 24.8, 23.6, 13.6; HRMS (ESI) calcd for C₁₉H₂₇BNO₃ [M+H]⁺ 328.2079, found 328.2087; HPLC (two AD-H series, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 22.1 min (maj.), *t*₂ = 27.2 min.

(-)-1-(1*H*-indol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexan-1-one (**3v**). 65 mg, 95% yield; 90% ee, $[\alpha]_{\text{D}}^{20} = -38.2$ (c 1.0 CHCl₃); Colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, *J* = 8.2 Hz, 1 H), 7.57 (d, *J* = 7.7 Hz, 1 H), 7.51 (d, *J* = 3.8 Hz, 1 H), 7.36-7.32 (m, 1 H), 7.28-7.24 (m, 1 H), 6.62 (d, *J* = 3.8 Hz, 1 H), 3.22-2.89 (m, 2 H), 1.63-1.51 (m, 2 H), 1.50-1.38 (m, 3 H), 1.28 and 1.25 (s each, 6:6 H), 0.95 (t, *J* = 7.1 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 135.8, 130.4, 125.0, 124.9, 123.5, 120.8, 116.7, 108.8, 83.3, 37.9, 32.8, 24.9, 24.8, 22.2, 14.4. HRMS (ESI) calcd for C₂₀H₂₉BNO₃ [M+H]⁺ 342.2235, found 342.2230; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 7.9 min (maj.), *t*₂ = 9.2 min.

(+)-3-Phenyl-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**5a**). 62 mg, 95% yield; 95% ee, $[\alpha]_{\text{D}}^{20} = +18.4$ (c 0.5 CHCl₃); white solid, mp 65-66 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.27 (m, 6 H), 7.23-7.16 (m,

1 H), 6.28-6.27 (m, 2 H), 3.42 (dd, $J = 17.5, 10.9$ Hz, 1 H), 3.21 (dd, $J = 17.5, 5.3$ Hz, 1 H), 2.87 (dd, $J = 10.8, 5.2$ Hz, 1 H), 1.25 and 1.18 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 141.2, 128.8, 128.5, 126.1, 119.1, 113.0, 83.8, 38.7, 24.7, 24.6; HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{25}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 326.1922, found: 326.1928; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 220 nm, flow rate: 0.7 mL/min), $t_1 = 6.6$ min (maj.), $t_2 = 7.2$ min.

(+)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*p*-tolyl)propan-1-one (**5b**). 63 mg, 93% yield; 94% ee, $[\alpha]_{\text{D}}^{20} = +14.0$ (*c* 1.0 CHCl_3); white solid, mp 77-79 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.33 (s, 2 H), 7.21 (d, $J = 8.0$ Hz, 2 H), 7.13 (d, $J = 7.9$ Hz, 2 H), 6.29-6.28 (m, 2 H), 3.40 (dd, $J = 17.5, 10.8$ Hz, 1 H), 3.19 (dd, $J = 17.5, 5.3$ Hz, 1 H), 2.84 (dd, $J = 10.8, 5.2$ Hz, 1 H), 2.34 (s, 3 H), 1.27 and 1.20 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 138.0, 135.4, 129.5, 128.3, 119.1, 112.9, 83.7, 38.9, 24.63, 24.62, 21.1; HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{27}\text{BNO}_3$ $[\text{M}+\text{H}]^+$ 340.2079, found 340.2087; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.5 mL/min), $t_1 = 10.1$ min (maj.), $t_2 = 11.0$ min.

(+)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*m*-tolyl)propan-1-one (**5c**). 62 mg, 92% yield; 94% ee, $[\alpha]_{\text{D}}^{20} = +12.9$ (*c* 1.0 CHCl_3); white solid, mp 58-59 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.33 (s, 2 H), 7.22-7.19 (m, 1 H), 7.11 (d, $J = 8.8$ Hz, 2 H), 7.02 (d, $J = 7.5$ Hz, 1 H), 6.29-6.28 (m, 2 H), 3.42 (dd, $J = 17.5, 11.0$ Hz, 1 H), 3.20 (dd, $J = 17.5, 5.2$ Hz, 1 H), 2.84 (dd, $J = 11.0, 5.1$ Hz, 1 H), 2.35 (s, 3 H), 1.27, 1.20 (s each, 6:6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.5, 141.0,

138.3, 129.3, 128.6, 126.8, 125.4, 119.1, 112.9, 83.7, 38.8, 24.61, 24.59, 21.5; HRMS (ESI) calcd for $C_{20}H_{27}BNO_3$ $[M+H]^+$ 340.2079, found 340.2082; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 7.0 min (maj.), t_2 = 7.5 min.

(+)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(*o*-tolyl)propan-1-one (**5d**). 59 mg, 87% yield; 90% ee, $[\alpha]_D^{20}$ = +0.4 (*c* 1.0 $CHCl_3$); Colorless liquid; 1H NMR (400 MHz, $CDCl_3$) δ 7.32 (s, 2 H), 7.29-7.27 (m, 1 H), 7.18-7.14 (m, 2 H), 7.12-7.08 (m, 1 H), 6.28-6.27 (m, 2 H), 3.40 (dd, J = 16.9, 10.2 Hz, 1 H), 3.14 (dd, J = 17.0, 5.0 Hz, 1 H), 3.09 (dd, J = 10.1 Hz, 5.0 Hz, 1 H), 2.40 (s, 3 H), 1.26 and 1.18 (s each, 6:6 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.7, 139.6, 136.5, 130.8, 127.8, 126.3, 126.0, 119.1, 113.0, 83.7, 38.1, 24.7, 24.6, 20.1; HRMS (ESI) calcd for $C_{20}H_{27}BNO_3$ $[M+H]^+$ 340.2079, found 340.2082; enantioselectivity was determined by chiral HPLC analysis of the corresponding β -hydroxy compound (-)-**6e** by oxidation of (+)-**5d** with sodium perborate.

(+)-3-(4-Methoxyphenyl)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**5e**). 66 mg, 93% yield; 96% ee, $[\alpha]_D^{20}$ = +15.2 (*c* 0.5 $CHCl_3$); white solid, mp 70-72 °C; 1H NMR (400 MHz, $CDCl_3$) δ 7.31 (s, 2 H), 7.21 (d, J = 8.6 Hz, 2 H), 6.84 (d, J = 8.6 Hz, 2 H), 6.27-6.26 (m, 2 H), 3.78 (s, 3 H), 3.36 (dd, J = 17.5, 10.7 Hz, 1 H), 3.17 (dd, J = 17.5, 5.4 Hz, 1 H), 2.80 (dd, J = 10.6, 5.3 Hz, 1 H), 1.24 and 1.18 (s each, 6:6 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.6, 158.0, 133.1, 129.4, 119.1, 114.2, 113.0, 83.7, 55.3, 39.0, 24.7, 24.6; HRMS (ESI) calcd for $C_{20}H_{27}BNO_4$ $[M+H]^+$ 356.2028, found 356.2034; HPLC (AD-H, elute:

Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 11.5 min (maj.), t_2 = 13.0 min.

(+)-3-(4-Fluorophenyl)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**5f**). 64 mg, 94% yield; 96% ee, $[\alpha]_D^{20}$ = +8.5 (*c* 0.4 CHCl₃); white solid, mp 77-79 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 2 H), 7.25 (dd, *J* = 8.0, 5.1 Hz, 2 H), 7.00-6.96 (m, 2 H), 6.28-6.27 (m, 2 H), 3.36 (dd, *J* = 17.5, 10.4 Hz, 1 H), 3.18 (dd, *J* = 17.5, 5.5 Hz, 1 H), 2.84 (dd, *J* = 10.3, 5.5 Hz, 1 H), 1.24 and 1.18 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.3, 161.4 (d, *J* = 242.2 Hz), 136.8 (d, *J* = 3.3 Hz), 129.9 (d, *J* = 7.7 Hz), 119.1, 115.5 (d, *J* = 21.0 Hz), 113.1, 83.9, 38.7, 24.7, 24.6; HRMS (ESI) calcd for C₁₉H₂₄BFNO₃ [M+H]⁺ 344.1828, found 344.1835; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 8.9 min (maj.), t_2 = 11.5 min.

(+)-3-(4-Chlorophenyl)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**5g**). 60 mg, 83% yield; 94% ee, $[\alpha]_D^{20}$ = +7.6 (*c* 0.5 CHCl₃); white solid, mp 114-116 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.19 (m, 6 H), 6.28-6.27 (m, 2 H), 3.37 (dd, *J* = 17.5, 10.3 Hz, 1 H), 3.19 (dd, *J* = 17.5, 5.5 Hz, 1 H), 2.84 (dd, *J* = 10.3, 5.5 Hz, 1 H), 1.24 and 1.18 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 139.8, 131.8, 129.8, 128.9, 119.1, 113.1, 84.0, 38.4, 24.7, 24.6; HRMS (ESI) calcd for C₁₉H₂₄BClNO₃ [M+H]⁺ 360.1532, found 360.1532; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 11.8 min (maj.), t_2 = 14.2 min.

(+)-3-(Naphthalen-1-yl)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxabor

olan-2-yl)propan-1-one (**5h**). 65 mg, 86% yield; 91% ee, $[\alpha]_{\text{D}}^{20} = +3.5$ (c 1.0 CHCl₃); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.3 Hz, 1 H), 7.88-7.85 (m, 1 H), 7.73 (d, *J* = 8.1 Hz, 1 H), 7.55-7.46 (m, 3 H), 7.45-7.41 (m, 1 H), 7.31 (s, 2 H), 6.27-6.26 (m, 2 H), 3.67 (dd, *J* = 10.5, 4.7 Hz, 1 H), 3.55 (dd, *J* = 17.4, 10.5 Hz, 1 H), 3.29 (dd, *J* = 17.3, 4.8 Hz, 1 H), 1.29 and 1.19 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 137.8, 134.4, 132.1, 129.0, 126.9, 126.1, 126.0, 125.74, 125.70, 124.0, 119.2, 113.0, 84.0, 38.4, 24.8, 24.7; HRMS (ESI) calcd for C₂₃H₂₇BNO₃ [M+H]⁺ 376.2079, found 376.2070; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 98/2, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 11.9 min, *t*₂ = 12.9 min (maj.).

(-)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(thiophen-2-yl)propan-1-one (**5i**). 61 mg, 92% yield; 96% ee, $[\alpha]_{\text{D}}^{20} = -25.0$ (c 0.1 CHCl₃); pale yellow solid, mp 92-94 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 2 H), 7.12 (d, *J* = 5.1 Hz, 1 H), 6.94-6.90 (m, 2 H), 6.28 (s, 2 H), 3.40 (dd, *J* = 17.4, 10.3 Hz, 1 H), 3.30 (dd, *J* = 17.5, 5.1 Hz, 1 H), 3.15 (dd, *J* = 10.2, 5.1 Hz, 1 H), 1.27 and 1.22 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 143.8, 127.1, 124.7, 123.5, 119.1, 113.1, 84.1, 39.5, 24.7, 24.6; HRMS (ESI) calcd for C₁₇H₂₃BNO₃S [M+H]⁺ 332.1486, found 332.1491; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 8.0 min (maj.), *t*₂ = 8.7 min.

(-)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-1-one (**5j**). 49 mg, 92% yield; 93% ee, $[\alpha]_{\text{D}}^{20} = -4.8$ (c 1.0 CHCl₃); white solid, mp 46-48 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 2 H), 6.27-6.25 (m, 2 H), 2.99-2.87 (m, 2 H), 1.55-1.45 (m, 1 H), 1.24 and 1.23 (s each, 6:6 H), 1.08 (d, *J* = 7.5 Hz, 3 H); ¹³C NMR

(100 MHz, CDCl₃) δ 170.9, 119.1, 112.8, 83.4, 38.4, 24.8, 24.7, 15.2; HRMS (ESI) calcd for C₁₄H₂₃BNO₃ [M+H]⁺ 264.1766, found 264.1771; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 5.9 min (maj.), t_2 = 6.3 min.

(-)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentan-1-one (**5k**). 40 mg, 73% yield; 84% ee, $[\alpha]_D^{20}$ = -7.3 (*c* 0.4 CHCl₃); yellow liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.32 (s, 2 H), 7.27-7.26 (m, 2 H), 3.01-2.89 (m, 2 H), 1.61-1.54 (m, 1 H), 1.51-1.39 (m, 2 H), 1.25 and 1.23 (s each, 6:6 H), 0.97 (t, *J* = 7.3 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 119.2, 112.8, 83.4, 36.2, 24.9, 24.8, 23.6, 13.5; HRMS (ESI) calcd for C₁₅H₂₅BNO₃ [M+H]⁺ 278.1922, found 278.1926; HPLC (two AD-H series, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), t_1 = 22.6 min (maj.), t_2 = 23.5 min.

(-)-1-(1*H*-pyrrol-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexan-1-one (**5l**). 45 mg, 77% yield; 90% ee, $[\alpha]_D^{20}$ = -9.6 (*c* 0.5 CHCl₃); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 2 H), 6.27-6.25 (m, 2 H), 2.99-2.89 (m, 2 H), 1.55-1.45 (m, 2 H), 1.43-1.33 (m, 3 H), 1.24 and 1.22 (s each, 6:6 H), 0.91 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.1, 119.2, 112.8, 83.3, 36.5, 32.8, 24.9, 24.8, 22.1, 14.4; HRMS (ESI) calcd for C₁₆H₂₇BNO₃ [M+H]⁺ 292.2079, found 292.2073; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.5 mL/min), t_1 = 11.4 min (maj.), t_2 = 11.9 min.

A typical procedure for the Oxidation of the borylated products – Oxidation of (S)-(5a). By means of a modified procedure as reported in reference 25, a mixture

of (*S*)-**5a** (65 mg, 0.2 mmol) and sodium perborate (154 mg, 1.0 mmol) in THF/water (2 mL, v/v = 1:1) was stirred at ambient temperature for 2 h. The mixture was then concentrated in vacuo, and the resultant residue was purified by silica gel column chromatography (eluent: petroleum ether (60-90 °C)/EtOAc = 10:1, v/v) to afford (-)-**6e** as a white solid (38 mg, 89%).

(-)-3-hydroxy-1-(1*H*-indol-1-yl)-3-phenylpropan-1-one (**6a**). 48 mg, 90% yield; ee 95%, $[\alpha]_D^{20} = -66.2$ (c 1.0 CHCl₃); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 7.8 Hz, 1 H), 7.58 (d, *J* = 7.7 Hz, 1 H), 7.49-7.47 (m, 2 H), 7.43-7.29 (m, 6 H), 6.64 (d, *J* = 3.8 Hz, 1 H), 5.41 (d, *J* = 8.8 Hz, 1 H), 3.72 (s, 1 H), 3.56-3.22 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 142.4, 135.6, 130.5, 128.8, 128.0, 125.9, 125.5, 124.4, 124.1, 121.1, 116.8, 110.0, 70.1, 45.0; HRMS (ESI) calcd for C₁₇H₁₄NO [M-OH]⁺ 248.1070, found 280.1064; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 34.1 min, *t*₂ = 36.9 min (maj.).

(-)-3-Hydroxy-1-(3-methyl-1*H*-indol-1-yl)-3-phenylpropan-1-one (**6b**). 50 mg, 89% yield; 92% ee, $[\alpha]_D^{20} = -70.8$ (c 0.5 CHCl₃); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1 H), 7.51-7.46 (m, 3 H), 7.42-7.30 (m, 5 H), 7.13 (s, 1 H), 5.40 (dd, *J* = 8.8, 3.1 Hz, 1 H), 3.80 (br, 1 H), 3.31-3.19 (m, 2 H), 2.26 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.3, 142.5, 135.9, 131.6, 128.8, 128.0, 125.9, 125.5, 123.9, 121.3, 119.3, 119.1, 116.8, 70.1, 45.0, 9.8; HRMS (ESI) calcd for C₁₈H₁₈NO₂ [M+H]⁺ 280.1332, found 280.1339; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 15.2 min, *t*₂ = 16.7 min (maj.).

(-)-3-Hydroxy-1-(1*H*-indol-1-yl)-3-(*o*-tolyl)propan-1-one (**6c**). 42 mg, 76% yield;

90% ee, $[\alpha]_{\text{D}}^{20} = -76.9$ (c 0.2 CHCl_3); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 7.8$ Hz, 1 H), 7.63 (d, $J = 7.6$ Hz, 1 H), 7.58 (d, $J = 7.7$ Hz, 1 H), 7.41-7.37 (m, 2 H), 7.31 (t, $J = 7.7$ Hz, 2 H), 7.21 (dd, $J = 16.6, 7.0$ Hz, 2 H), 6.65 (d, $J = 3.8$ Hz, 1 H), 5.65 (d, $J = 9.4$ Hz, 1 H), 3.56 (d, $J = 2.5$ Hz, 1 H), 3.29 (dd, $J = 17.0, 9.4$ Hz, 1 H), 3.19 (dd, $J = 17.0, 2.5$ Hz, 1 H), 2.40 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.9, 140.5, 135.7, 135.0, 134.3, 130.7, 127.9, 126.7, 125.6, 125.5, 124.4, 124.2, 121.1, 116.8, 110.1, 66.7, 43.8, 19.3; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{17}\text{NNaO}_2$ $[\text{M}+\text{Na}]^+$ 302.1151, found 302.1151; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 16.8$ min, $t_2 = 24.6$ min (maj.).

(-)-3-Hydroxy-1-(1*H*-indol-1-yl)-3-(naphthalen-1-yl)propan-1-one (**6d**). 57 mg, 90% yield; 87% ee, $[\alpha]_{\text{D}}^{20} = -53.0$ (c 0.1 CHCl_3); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.54 (d, $J = 6.9$ Hz, 1 H), 8.09 (d, $J = 7.7$ Hz, 1 H), 7.93-7.91 (m, 1 H), 7.84 (d, $J = 7.6$ Hz, 2 H), 7.58-7.50 (m, 4 H), 7.40 (t, $J = 7.7$ Hz, 1 H), 7.33-7.26 (m, 2 H), 6.60 (d, $J = 3.6$ Hz, 1 H), 6.22 (dd, $J = 8.5, 2.7$ Hz, 1 H), 3.84 (br, 1 H), 3.46-3.35 (m, 2 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.9, 138.0, 135.7, 133.9, 130.6, 129.9, 129.2, 128.4, 126.6, 125.80, 125.76, 125.5, 124.4, 124.2, 123.4, 122.8, 121.1, 116.8, 110.0, 67.0, 44.4; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{16}\text{NO}$ $[\text{M}-\text{OH}]^+$ 298.1226, found 298.1233; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 20.7$ min, $t_2 = 26.9$ min (maj.).

(-)-3-Hydroxy-3-phenyl-1-(1*H*-pyrrol-1-yl)propan-1-one (**6e**). 38 mg, 89% yield; 94% ee, $[\alpha]_{\text{D}}^{20} = -85.6$ (c 0.5 CHCl_3); white solid, mp 76-78 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.45-7.37 (m, 4 H), 7.34-7.26 (m, 3 H), 6.31-6.30 (m, 2 H), 5.35 (dd, $J = 9.1$,

3.2 Hz, 1 H), 3.44 (br, 1 H), 3.26 (dd, $J = 17.1, 9.1$ Hz, 1 H), 3.17 (dd, $J = 17.1, 3.2$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 142.4, 128.8, 128.1, 125.8, 119.1, 113.8, 70.0, 43.9; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{12}\text{NO}$ $[\text{M}-\text{OH}]^+$ 198.0913, found 198.0913; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 19.7$ min (maj.), $t_2 = 21.9$ min.

(-)-3-Hydroxy-1-(1*H*-pyrrol-1-yl)-3-(*o*-tolyl)propan-1-one (**6f**). 40 mg, 87% yield; 90% ee, $[\alpha]_{\text{D}}^{20} = -96.5$ (c 0.2 CHCl_3); white solid, mp 63-65 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 7.5$ Hz, 1 H), 7.34-7.29 (m, 3 H), 7.22 (t, $J = 8.6$ Hz, 1 H), 6.36-6.35 (m, 2 H), 5.60 (dd, $J = 9.4, 2.5$ Hz, 1 H), 3.43 (br, 1 H), 3.24 (dd, $J = 17.1, 9.4$ Hz, 1 H) and 3.13 (dd, $J = 17.1, 2.6$ Hz, 1 H), 2.41 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.9, 140.4, 134.2, 130.7, 127.9, 126.6, 125.5, 119.1, 113.8, 66.5, 42.7, 19.2; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{15}\text{NNaO}_2$ $[\text{M}+\text{Na}]^+$ 252.0995, found 252.0998; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 90/10, detector: 254 nm, flow rate: 0.7 mL/min), $t_1 = 16.8$ min, $t_2 = 19.2$ min (maj.).

Derivations of the borylated products

A solution of NaOMe (12 mg, 0.22 mmol) in MeOH (1 mL) was added to a stirred solution of (*S*)-**3a** (75 mg, 0.2 mmol) in dry THF (1 mL) at 0 °C. After the reaction mixture was stirred at 0 °C for 30 min, aqueous NH_4Cl (10 mL) was added to quench the reaction and the mixture was extracted with Et_2O (3×10 mL). The combined organic layer was dried over Na_2SO_4 and concentrated under reduced pressure. The corresponding methyl ester was observed in <10% yield with 100% conversion of (*S*)-**3a** by ^1H NMR analysis using CH_2Br_2 as the internal standard. Compound (*S*)-**5a**

was treated in a similar fashion.

Pyrrolidine (71 mg, 1.0 mmol) was added to a stirred solution of (*S*)-**3a** (38 mg, 0.1 mmol) in dry THF (2 mL), and the mixture was then stirred at 60 °C for 12 h. After cooled to ambient temperature, all the volatiles were removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether (60-90 °C)/EtOAc = 15:1, v/v) to afford (*S*)-**7** as a pale yellow solid (26 mg, 80%). Compound (*S*)-**5a** was treated in a similar fashion to afford (*S*)-**7** (23 mg, 71%).

(+)-3-Phenyl-1-(pyrrolidin-1-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**7**).^{12j} 26 mg, 80% yield; 94% ee, $[\alpha]_D^{20} = +7.5$ (c 0.2 CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.27-7.21 (m, 4 H), 7.13-7.09 (m, 1 H), 3.50 (t, *J* = 6.8 Hz, 2 H), 3.43-3.29 (m, 2 H), 2.81 (dd, *J* = 16.6, 10.7 Hz, 1 H), 2.73 (dd, *J* = 16.6, 6.7 Hz, 1 H₂), 2.62 (dd, *J* = 10.7, 6.7 Hz, 1 H), 1.96-1.83 (m, 4 H), 1.13 (s, 12 H); ¹³C NMR (100 MHz, CDCl₃) δ 173.2, 143.3, 128.4, 128.2, 125.1, 82.3, 46.8, 46.3, 39.2, 26.0, 24.5, 24.82, 24.79; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 95/5, detector: 220 nm, flow rate: 0.7 mL/min), *t*₁ = 18.5 min, *t*₂ = 20.1 min (maj.).

Control reactions

Under a nitrogen atmosphere, a mixture of CuI (1.9 mg, 0.01 mmol), (*R,S*)-JosiPhos (9.6 mg, 0.015 mmol), and K₃PO₄ (4.2 mg, 0.02 mmol) in *t*-AmOH (1 mL) was stirred at ambient temperature for 30 min, followed by the addition of B₂pin₂ (**2**) (51 mg, 0.2 mmol) in *t*-AmOH (0.5 mL). After the mixture was stirred at ambient temperature for 10 min, (*E*)-1-(1*H*-indol-1-yl)-3-phenylprop-2-en-1-one (**1a**)

(49 mg, 0.2 mmol) and (*E*)-3-phenyl-1-(1H-pyrrol-1-yl)prop-2-en-1-one (**4a**) (39 mg, 0.2 mmol) in *t*-AmOH (0.5 mL) was added. The resultant mixture was stirred at ambient temperature for 20 h, filtered through a short pad of celite, and rinsed with 20 mL EtOAc. All the volatiles were removed under reduced pressure, the yield of (*S*)-**3a** and (*S*)-**5a** was determined by ¹H NMR analysis using CH₂Br₂ (0.2 mmol) as the internal standard.

Pyrrolidine (7.1 mg, 0.1 mmol) was added to a stirred solution of (*S*)-**3a** (38 mg, 0.1 mmol) and (*S*)-**5a** (32.5 mg, 0.1 mmol) in dry THF (2 mL), and the resultant mixture was then stirred at 60 °C for 12 h. After cooled to ambient temperature, all the volatiles were removed under reduced pressure. The conversion of (*S*)-**3a** and (*S*)-**5a** was determined by ¹H NMR analysis using CH₂Br₂ (0.2 mmol) as the internal standard.

(*S*)-1,3-diphenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-one (**10**).²³ 53 mg, 79% yield; 90% ee, [α]_D²⁰ = +2.8 (*c* 0.5 CHCl₃); white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.97 (m, 2 H), 7.55 (t, *J* = 7.4 Hz, 1 H), 7.45 (t, *J* = 7.6 Hz, 2 H), 7.36-7.29 (m, 4 H), 7.21-7.17 (m, 1H), 3.59 (dd, *J* = 18.3, 10.9 Hz, 1 H), 3.44 (dd, *J* = 18.3, 5.0 Hz, 1 H), 2.84 (dd, *J* = 10.9, 5.0 Hz, 1 H), 1.28 and 1.20 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 199.7, 142.0, 136.8, 133.0, 128.6, 128.5, 128.4, 128.1, 125.6, 83.4, 43.3, 24.63, 24.59; HPLC (AD-H, elute: Hexanes/*i*-PrOH = 99/1, detector: 254 nm, flow rate: 0.7 mL/min), *t*₁ = 15.3 min (maj.), *t*₂ = 26.4 min.

(*S*)-benzyl 3-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propanoate (**11**).²⁴ 57 mg, 78% yield; 84% ee, [α]_D²⁰ = +17.0 (*c* 1.0 CHCl₃); colorless liquid; ¹H

NMR (400 MHz, CDCl₃) δ 7.37-7.21 (m, 10 H), 7.18-7.13 (m, 1 H), 5.16-5.06 (m, 2 H), 2.96 (dd, J = 15.3, 8.8 Hz, 1 H), 2.81-2.71 (m, 2 H), 1.20 and 1.15 (s each, 6:6 H); ¹³C NMR (100 MHz, CDCl₃) δ 173.3, 141.4, 136.2, 128.60, 128.57, 128.3, 128.20, 128.16, 125.8, 83.7, 66.2, 37.4, 24.7, 24.6; HPLC (two AD-H series, elute: Hexanes/*i*-PrOH = 99/1, detector: 220 nm, flow rate: 0.7 mL/min), t_1 = 34.1 min (maj.), t_2 = 36.9 min.

ASSOCIATED CONTENT

Supporting Information Available

NMR spectra of the substrates and products, and HPLC analysis for racemic and chiral products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: zkyu@dicp.ac.cn (Z.K.Y.)

Author Contributions

¹Q.B.J., T.L.G., and R.L.G. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGEMENTS

We are grateful to the National Natural Science Foundation of China (21472185).

REFERENCES

(1) (a) *Catalytic Asymmetric Synthesis*, 3rd ed., Chapter 8A, Ojima, I., Eds.; Wiley: New York, **2010**. (b) *Comprehensive Asymmetric Catalysis: Supplement 2*, Chapter 31, Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H., Springer: Berlin, **2004**.

(2) (a) Breman, A. C.; Telderman, S. E. M.; van Santen, R. P. M.; Scott, J. I.; van Maarseveen, J. H.; Ingemann, S.; Hiemstra, H. *Cinchona* Alkaloid Catalyzed Sulfa-Michael Addition Reactions Leading to Enantiopure β -Functionalized Cysteines. *J. Org. Chem.* **2015**, *80*, 10561-10574. (b) Liu, Y.; Sun, B.; Wang, B.; Wakem, M.; Deng, L. Catalytic Asymmetric Conjugate Addition of Simple Alkyl Thiols to α,β -Unsaturated *N*-Acylated Oxazolidin-2-ones with Bifunctional Catalysts. *J. Am. Chem. Soc.* **2009**, *131*, 418-419.

(3) (a) Li, K.; Wan, Q.; Kang, Q. Chiral-at-Metal Rh(III) Complex Catalyzed Asymmetric Conjugate Addition of Unactivated Alkenes with α,β -Unsaturated 2-Acyl Imidazoles. *Org. Lett.* **2017**, *19*, 3299-3302. (b) Huo, H.; Harms, K.; Meggers, E. Catalytic, Enantioselective Addition of Alkyl Radicals to Alkenes via Visible-Light-Activated Photoredox Catalysis with a Chiral Rhodium Complex. *J. Am. Chem. Soc.* **2016**, *138*, 6936-6939. (c) Drissi-Amraoui, S.; Morin, M. S. T.; Crévisy, C.; Baslé, O.; Marcia de Figueiredo, R.; Mauduit, M.; Campagne, J. Copper-Catalyzed Asymmetric Conjugate Addition of Dimethylzinc to Acyl-*N*-methylimidazole Michael Acceptors: a Powerful Synthetic Platform. *Angew. Chem. Int. Ed.* **2015**, *54*, 11830-11834.

(4) (a) Wang, G.; Tang, Y.; Zhang, Y.; Liu, X.; Lin, L.; Feng, X. Enantioselective Synthesis of *N*-H-Free 1,5-Benzothiazepines. *Chem.-Eur. J.* **2017**, *23*, 554-557. (b)

Yao, Q.; Wang, Z.; Zhang, Y.; Liu, X.; Lin, L.; Feng, X. *N,N'*-Dioxide/Gadolinium(III)-Catalyzed Asymmetric Conjugate Addition of Nitroalkanes to α,β -Unsaturated Pyrazolamides. *J. Org. Chem.* **2015**, *80*, 5704-5712. (c) Zhang, J.; Liu, X.; Wang, R. Magnesium Complexes as Highly Effective Catalysts for Conjugate Cyanation of α,β -Unsaturated Amides and Ketones. *Chem.-Eur. J.* **2014**, *20*, 4911-4915.

(5) (a) Hatano, M.; Yamakawa, K.; Ishihara, K. Enantioselective Conjugate Hydrocyanation of α,β -Unsaturated *N*-Acylpyrroles Catalyzed by Chiral Lithium(I) Phosphoryl Phenoxide. *ACS Catal.* **2017**, *7*, 6686-6690. (b) Sakaguchi, Y.; Kurono, N.; Yamauchi, K.; Ohkuma, T. Asymmetric Conjugate Hydrocyanation of α,β -Unsaturated *N*-Acylpyrroles with the $\text{Ru}(\text{phgly})_2(\text{binap})\text{-CH}_3\text{OLi}$ Catalyst System. *Org. Lett.* **2014**, *16*, 808-811. (c) Du, D.; Duan, W.-L. Palladium-catalyzed 1,4-addition of diarylphosphines to α,β -unsaturated *N*-acylpyrroles. *Chem. Commun.* **2011**, *47*, 11101-11103. (d) Zhao, D.; Mao, L.; Wang, Y.; Yang, D.; Zhang, Q.; Wang, R. Catalytic Asymmetric Hydrophosphinylation of α,β -Unsaturated *N*-Acylpyrroles: Application of Dialkyl Phosphine Oxides in Enantioselective Synthesis of Chiral Phosphine Oxides or Phosphines. *Org. Lett.* **2010**, *12*, 1880-1882. (e) Zhao, D.; Wang, Y.; Mao, L.; Wang, R. Highly Enantioselective Conjugate Additions of Phosphites to α,β -Unsaturated *N*-Acylpyrroles and Imines: A Practical Approach to Enantiomerically Enriched Amino Phosphonates. *Chem.-Eur. J.* **2009**, *15*, 10983-10987. (f) Mita, T.; Sasaki, K.; Kanai, M.; Shibasaki, M. Catalytic Enantioselective Conjugate Addition of Cyanide to α,β -Unsaturated *N*-Acylpyrroles. *J.*

1
2
3
4 *Am. Chem. Soc.* **2005**, *127*, 514-515. (g) Matsunaga, S.; Kinoshita, T.; Okada, S.;
5
6 Harada, S.; Shibasaki, M. Catalytic Asymmetric 1,4-Addition Reactions Using
7
8 α,β -Unsaturated *N*-Acylpyrroles as Highly Reactive Monodentate α,β -Unsaturated
9
10 Ester Surrogates. *J. Am. Chem. Soc.* **2004**, *126*, 7559-7570.
11
12

13 (6) Goldys, A. M.; McErlean, C. S. P. *N*-Acylpyrroles: More Than Amides. *Eur. J.*
14
15 *Org. Chem.* **2012**, 1877-1888.
16
17

18 (7) (a) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, P. N.; Kim, C. H.; Verma, A.
19
20 K.; Choi, E. H. Biomedical Importance of Indoles. *Molecules* **2013**, *18*, 6620-6662. (b)
21
22 Finefield, J. M.; Frisvad, J. C.; Sherman, D. H.; Williams, R. M. Fungal Origins of the
23
24 Bicyclo[2.2.2]diazaoctane Ring System of Prenylated Indole Alkaloids. *J. Nat. Prod.*
25
26 **2012**, *75*, 812-833.
27
28

29
30 (8) Trost, B. M.; Hirano, K. Dinuclear Zinc Catalyzed Asymmetric Spirannulation
31
32 Reaction: An Umpolung Strategy for Formation of α -Alkylated- α -Hydroxyoxindoles.
33
34 *Org. Lett.* **2012**, *14*, 2446-2449.
35
36

37 (9) *Synthesis and Applications of Organoboron Compounds, Topics in*
38
39 *Organometallic Chemistry*, Fernández, E.; Whiting, A., Eds.; Springer: Heidelberg,
40
41 **2015**.
42
43

44
45 (10) For reviews, see: (a) Leonori, D.; Aggarwal, V. K. Stereospecific Couplings of
46
47 Secondary and Tertiary Boronic Esters. *Angew. Chem., Int. Ed.* **2015**, *54*, 1082-1096.
48
49 (b) Leonori, D.; Aggarwal, V. K. Lithiation-Borylation Methodology and Its
50
51 Application in Synthesis. *Acc. Chem. Res.* **2014**, *47*, 3174-3183. (c) Scott, H. K.;
52
53 Aggarwal, V. K. Highly Enantioselective Synthesis of Tertiary Boronic Esters and
54
55
56
57
58
59
60

their Stereospecific Conversion to other Functional Groups and Quaternary Stereocentres. *Chem.-Eur. J.* **2011**, *17*, 13124-13132. (d) Crudden, C. M.; Glasspoole, B. W.; Lata, C. J. Expanding the scope of transformations of organoboron species: carbon-carbon bond formation with retention of configuration. *Chem. Commun.* **2009**, 6704-6716.

(11) For reviews, see: (a) Neeve, E. C.; Geier, S. J.; Mkhaliid, I. A. I.; S. A. Westcott, S. A.; Marder, T. B. Diboron(4) Compounds: From Structural Curiosity to Synthetic Workhorse. *Chem. Rev.* **2016**, *116*, 9091-9161. (b) Stavber, G.; Časar, Z. Cu^{II} and Cu⁰ Catalyzed Mono Borylation of Unsaturated Hydrocarbons with B₂pin₂: Entering into the Water. *ChemCatChem* **2014**, *6*, 2162-2174. (c) Cid, J.; Gulyás, H.; Carbó, J. J.; Fernández, E. Trivalent boron nucleophile as a new tool in organic synthesis: reactivity and asymmetric induction. *Chem. Soc. Rev.* **2012**, *41*, 3558-3570. (d) Calow, A. D. J.; Whiting, A. Catalytic methodologies for the β -boration of conjugated electron deficient alkenes. *Org. Biomol. Chem.* **2012**, *10*, 5485-5497. (e) Hartmann, E.; Vyas, D. J.; Oestreich, M. Enantioselective formal hydration of α,β -unsaturated acceptors: asymmetric conjugate addition of silicon and boron nucleophiles. *Chem. Commun.* **2011**, *47*, 7917-7932; (f) Schiffner, J. A.; Mütter, K.; Oestreich, M. Enantioselective Conjugate Borylation. *Angew. Chem., Int. Ed.* **2010**, *49*, 1194-1196. (g) Lillo, V.; Bonet A.; Fernández, E. Asymmetric induction on β -boration of α,β -unsaturated compounds: an inexpensive approach. *Dalton Trans.*, **2009**, 2899-2908.

(12) Selected recent reports, see: (a) Chen, L.; Zou, X.; Zhao, H.; Xu, S.

Copper-Catalyzed Asymmetric Protoboration of β -Amidoacrylonitriles and β -Amidoacrylate Esters: An Efficient Approach to Functionalized Chiral α -Amino Boronate Esters. *Org. Lett.* **2017**, *19*, 3676-3679. (b) Jiang, Q. B.; Guo, T. L.; Yu, Z. K. Copper-Catalyzed Asymmetric Borylation: Construction of a Stereogenic Carbon Center Bearing Both CF_3 and Organoboron Functional Groups. *J. Org. Chem.* **2017**, *82*, 1951-1960 and references cited therein. (c) Xie, J.-B.; Lin, S.; Qiao, S.; Li, G. Asymmetric Catalytic Enantio- and Diastereoselective Boron Conjugate Addition Reactions of α -Functionalized α,β -Unsaturated Carbonyl Substrates. *Org. Lett.* **2016**, *18*, 3926-3929. (d) Niu, Z.; Chen, J.; Chen, Z.; Ma, M.; Song, C.; Ma, Y. Application of Bidentate Oxazoline–Carbene Ligands with Planar and Central Chirality in Asymmetric β -Boration of α,β -Unsaturated Esters. *J. Org. Chem.* **2015**, *80*, 602-608. (e) Xie, J.-B.; Lin, S.; Luo, J.; Wu, J.; Winn, T. R.; Li, G. Asymmetric boron conjugate addition to α,β -unsaturated carbonyl compounds catalyzed by $\text{CuOTf}/\text{Josiphos}$ under non-alkaline conditions. *Org. Chem. Front.* **2015**, *2*, 42-46. (f) Jiang, Q. B.; Guo, T. L.; Yu, Z. K. Copper-Catalyzed Tandem Asymmetric Borylation of β -Chloroalkyl Aryl Ketones and Related Compounds. *ChemCatChem* **2015**, *7*, 660-665. (g) He, Z.-T.; Zhao, Y.-S.; Tian, P.; Wang, C.-C.; Dong, H.-Q.; Lin, G.-Q. Copper-Catalyzed Asymmetric Hydroboration of α -Dehydroamino Acid Derivatives: Facile Synthesis of Chiral β -Hydroxy- α -amino Acids. *Org. Lett.* **2014**, *16*, 1426-1429. (h) Molander, G. A.; Wisniewski, S. R.; Hosseini-Sarvari, M. Synthesis and Suzuki–Miyaura Cross-Coupling of Enantioenriched Secondary Potassium β -Trifluoroboratoamides: Catalytic, Asymmetric Conjugate Addition of Bisboronic

Acid and Tetrakis(dimethylamino)diboron to α,β -Unsaturated Carbonyl Compounds. *Adv. Synth. Catal.* **2013**, 355, 3037-3057. (i) Kobayashi, S.; Xu, P.; Endo, T.; Ueno, M.; Kitanosono, T. Chiral Copper(II)-Catalyzed Enantioselective Boron Conjugate Additions to α,β -Unsaturated Carbonyl Compounds in Water. *Angew. Chem., Int. Ed.* **2012**, 51, 12763-12766. (j) Lee, J. C. H.; McDonald, R.; Hall, D. G. Enantioselective preparation and chemoselective cross-coupling of 1,1-diboron compounds. *Nature Chem.* **2011**, 3, 894-899. (k) Lee, J.-E.; Yun, J. Catalytic Asymmetric Boration of Acyclic α,β -Unsaturated Esters and Nitriles. *Angew. Chem., Int. Ed.* **2008**, 47, 145-147.

(13) (a) Shiomi, T.; Adachi, T.; Toribatake, K.; Zhou, L.; Nishiyama, H. Asymmetric β -boration of α,β -unsaturated carbonyl compounds promoted by chiral rhodium-bisoxazolinyphenyl catalyst. *Chem. Commun.* **2009**, 45, 5987-5989. (b) Lillo, V.; Geier, M. J.; Westcott, S. A.; Fernández, E. Ni and Pd mediate asymmetric organoboron synthesis with ester functionality at the β -position. *Org. Biomol. Chem.* **2009**, 7, 4674-4676.

(14) (a) Radomkit, S.; Hoveyda, A. H. Enantioselective Synthesis of Boron-Substituted Quaternary Carbon Stereogenic Centers through NHC-Catalyzed Conjugate Additions of (Pinacolato)boron Units to Enones. *Angew. Chem. Int. Ed.* **2014**, 53, 3387-3391. (b) Wu, H.; Radomkit, S.; O'Brien, J. M.; Hoveyda, A. H. Metal-Free Catalytic Enantioselective C-B Bond Formation: (Pinacolato)boron Conjugate Additions to α,β -Unsaturated Ketones, Esters, Weinreb Amides, and Aldehydes Promoted by Chiral NHeterocyclic Carbenes. *J. Am. Chem. Soc.* **2012**, 134,

8277-8285. (c) Bonet, A.; Gulyás, H.; Fernández, E. Metal-Free Catalytic Boration at the β -Position of α,β -Unsaturated Compounds: A Challenging Asymmetric Induction. *Angew. Chem., Int. Ed.* **2010**, *49*, 5130-5134.

(15) Illi, V. O. Phasentransfer-katalysierte *N*-Acylierung von Indol. *Synthesis*, **1979**, *5*, 387-388.

(16) Dang, L.; Lin, Z. DFT Studies on the Borylation of α,β -Unsaturated Carbonyl Compounds Catalyzed by Phosphine Copper(I) Boryl Complexes and Observations on the Interconversions between O- and C-Bound Enolates of Cu, B, and Si. *Organometallics* **2008**, *27*, 4443-4454.

(17) Yang, Y.; Duan, X.-H.; Deng, J.-Y.; Jin, B.; Jia, H.-M.; Liu, B.-L. Novel imaging agents for β -amyloid plaque based on the *N*-benzoylindole core. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5594-5597.

(18) Patil, D. V.; Cavitt, M. A.; France, S. Diastereoselective Intramolecular Friedel–Crafts Cyclizations of Substituted Methyl 2-(1*H*-indole-1-carbonyl)acrylates: Efficient Access to Functionalized 1*H*-Pyrrolo[1,2-*a*]indoles. *Org. Lett.* **2011**, *13*, 5820-5823.

(19) Oldroyd, D. L.; Weedon, A. C. Intramolecular Photochemical Cycloaddition Reactions of *N*-[(ω -Alkenyloxy)carbonyl]indoles and *N*-(ω -Alkenoyl)indoles. *J. Org. Chem.* **1994**, *59*, 1333-1343.

(20) Trost, B. M.; Ehmke, V. An Approach for Rapid Increase in Molecular Complexity: Atom Economic Routes to Fused Polycyclic Ring Systems. *Org. Lett.* **2014**, *16*, 2708-2711.

(21) Shintani, R.; Kimura, T.; Hayashi, T. Rhodium/diene-catalyzed asymmetric 1,4-addition of arylboronic acids to α,β -unsaturated Weinreb amides. *Chem. Commun.* **2005**, 3213-3214.

(22) Provencher, B. A.; Bartelson, K. J.; Liu, Y.; Foxman, B. M.; Deng, L. Structural Study-Guided Development of Versatile Phase-Transfer Catalysts for Asymmetric Conjugate Additions of Cyanide. *Angew. Chem. Int. Ed.* **2011**, 50, 10565-10569.

(23) Zhao, L.; Ma, Y.; He, F.; Duan, W.; Chen, J.; Song, C. Enantioselective β -Boration of Acyclic Enones by a [2.2]Paracyclophane-Based N-Heterocyclic Carbene Copper(I) Catalyst. *J. Org. Chem.* **2013**, 78, 1677-1681.

(24) Toribatake, K.; Zhou, L.; Tsuruta, A.; Nishiyama, H. Asymmetric β -boration of α,β -unsaturated carbonyl compounds with chiral Rh[bis(oxazolonyl)phenyl] catalysts. *Tetrahedron* **2013**, 69, 3551-3560.

(25) Sim, H.-S.; Feng, X.; Yun, J. Copper-Catalyzed Enantioselective β -Boration of Acyclic Enones. *Chem.-Eur. J.* **2009**, 15, 1939-1943.